

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **October 31, 2018**

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: **000-55940**

**BODY AND MIND INC.**

(Exact name of registrant as specified in its charter)

**NEVADA**

(State or other jurisdiction of organization)

**98-1319227**

(I.R.S. employer identification no.)

**750 – 1095 West Pender Street  
Vancouver, British Columbia, Canada**

(Address of principal executive offices)

**V6E 2M6**

(Zip code)

**(604) 376-3567**

(Registrant's telephone number, including area code)

**None**

(Former name, former address, and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

(Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes  No

The number of shares of Common Stock, \$0.0001 par value, of the registrant outstanding at December 17, 2018, was 68,479,141.

BODY AND MIND INC.  
FORM 10-Q  
TABLE OF CONTENTS

<b><u>PART 1. FINANCIAL INFORMATION</u></b>	<b>3</b>
<u>ITEM 1 – CONSOLIDATED INTERIM FINANCIAL STATEMENTS</u>	3
<u>ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</u>	17
<u>ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</u>	25
<u>ITEM 4 – CONTROLS AND PROCEDURES</u>	25
<i>(a) Evaluation of Disclosure Controls and Procedures</i>	25
<i>(b) Internal control over financial reporting</i>	26
<b><u>PART II – OTHER INFORMATION</u></b>	<b>27</b>
<u>ITEM 1 – LEGAL PROCEEDINGS</u>	27
<u>ITEM 1A. RISK FACTORS</u>	27
<u>ITEM 2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</u>	27
<u>ITEM 3 – DEFAULTS UPON SENIOR SECURITIES</u>	28
<u>ITEM 4 – MINE SAFTEY DISCLOSURES</u>	28
<u>ITEM 5 – OTHER INFORMATION</u>	28
<u>ITEM 6 – EXHIBITS</u>	28
<u>SIGNATURE</u>	29

## PART I. FINANCIAL INFORMATION

## ITEM 1. CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Body and Mind Inc.

Statement 1

## Consolidated Interim Balance Sheets

(U.S. Dollars)

	As at 31 October 2018 (Unaudited)	As at 31 July 2018
<b>ASSETS</b>		
<b>Current</b>		
Cash and cash equivalents	\$ 100,481	\$ 324,837
Amounts receivable	676,990	632,477
Prepays	170,218	99,014
Inventory (Note 3)	1,112,512	953,417
<b>Total current assets</b>	<b>2,060,201</b>	<b>2,009,745</b>
Investment in NMG Ohio LLC (Note 12)	99,242	77,600
Property and equipment (Note 4)	2,590,213	2,615,898
Brand and licenses (Note 10)	8,172,000	8,172,000
Goodwill (Note 10)	2,635,721	2,635,721
<b>TOTAL ASSETS</b>	<b>\$ 15,557,377</b>	<b>\$ 15,510,964</b>
<b>LIABILITIES</b>		
<b>Current</b>		
Accounts payables	\$ 550,288	\$ 447,703
Accrued liabilities	95,239	95,481
Income taxes	362,913	239,358
Due to related parties (Note 5)	10,075	51,081
Promissory notes (Note 6)	2,175,000	2,175,000
<b>Total current liabilities</b>	<b>3,193,515</b>	<b>3,008,623</b>
Deferred tax liability	1,716,120	1,716,120
<b>TOTAL LIABILITIES</b>	<b>4,909,635</b>	<b>4,724,743</b>
<b>STOCKHOLDERS' EQUITY</b>		
<b>Capital Stock— Statement 3 (Note 7)</b>		
Authorized:		
900,000,000 Common Shares – Par Value \$0.0001		
Issued and Outstanding:		
47,774,817 (31 July 2018 – 47,774,817) Common Shares	4,778	4,778
<b>Additional Paid-in Capital</b>	<b>16,918,082</b>	<b>16,918,082</b>
Shares to be issued (Note 11)	103,267	103,267
<b>Other Comprehensive Income</b>	<b>605,720</b>	<b>532,405</b>
<b>Deficit</b>	<b>(6,984,105)</b>	<b>(6,772,311)</b>
<b>TOTAL STOCKHOLDERS' EQUITY</b>	<b>10,647,742</b>	<b>10,786,221</b>
<b>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</b>	<b>\$ 15,557,377</b>	<b>\$ 15,510,964</b>

The accompanying notes are an integral part of these unaudited consolidated interim financial statements.

**Consolidated Interim Statements of Operations**

(Unaudited)

(U.S. Dollars)

	<b>Three Month Period Ended 31 October</b>	
	<b>2018</b>	<b>2017</b>
<b>Sales</b>	\$ 1,325,978	\$ -
<b>Sales tax</b>	(131,419)	-
<b>Cost of sales</b>	(737,621)	-
	<u>456,938</u>	<u>-</u>
<b>General and Administrative Expenses</b>		
Accounting and legal (Note 5)	78,381	226,733
Consulting fees	2,600	52,560
Depreciation	3,140	-
Insurance	22,238	-
Management fees (Note 5)	52,844	21,940
Office and miscellaneous	85,092	62,162
Regulatory, filing and transfer agent fees	7,196	10,850
Rent	18,362	-
Salaries and wages	194,175	-
Travel	2,023	2,472
	<u>(466,051)</u>	<u>(376,717)</u>
<b>Loss Before Other Items</b>	(9,113)	(376,717)
<b>Other Items</b>		
Foreign exchange, net	(71,554)	(72,903)
Interest income	48	-
Loss of equity investee (Note 12)	(7,620)	-
Write off of amounts receivable	-	(888)
<b>Net Loss for the Period Before Income Tax</b>	\$ (88,239)	\$ (450,508)
Income tax expense	(123,555)	-
<b>Net Loss for the Period</b>	(211,794)	(450,508)
<b>Other Comprehensive Income (Loss)</b>		
Foreign currency translation adjustment	73,315	(73,728)
<b>Comprehensive Loss for the Period</b>	\$ (138,479)	\$ (524,236)
<b>Loss per Share – Basic and Diluted</b>	\$ 0.00	\$ (0.02)
<b>Weighted Average Number of Shares Outstanding</b>	<u>47,774,817</u>	<u>19,137,658</u>

The accompanying notes are an integral part of these unaudited consolidated interim financial statements.

**Consolidated Interim Statements of Changes in Stockholders' Equity**

(Unaudited)

(U.S. Dollars)

	Share Capital Common Shares		Additional Paid-in Capital	Shares to be Issued	Other Comprehensive Income	Deficit	Total
	Number	Amount					
<b>Balance – 31 July 2017</b>	19,137,783	\$ 1,914	\$ 4,954,932	\$ -	\$ 356,828	\$ (4,991,251)	\$ 322,423
Private placements (Note 7)	9,739,534	974	5,025,520	-	-	-	5,026,494
Acquisition of Nevada Medical Group LLC (Notes 7 and 10)	18,827,000	1,883	6,335,482	135,202	-	-	6,472,567
Issuance of escrowed shares (Notes 7 and 10)	70,500	7	31,928	(31,935)	-	-	-
Share issue costs (Note 7)	-	-	(219,459)	-	-	-	(219,459)
Stock-based compensation (Note 7)	-	-	789,679	-	-	-	789,679
Foreign currency translation adjustment	-	-	-	-	175,577	-	175,577
Loss for the period	-	-	-	-	-	(1,781,060)	(1,781,060)
<b>Balance – 31 July 2018</b>	47,774,817	4,778	16,918,082	103,267	532,405	(6,772,311)	10,786,221
Foreign currency translation adjustment	-	-	-	-	73,315	-	73,315
Loss for the period	-	-	-	-	-	(211,794)	(211,794)
<b>Balance – 31 October 2018</b>	47,774,817	\$ 4,778	\$ 16,918,082	\$ 103,267	\$ 605,720	\$ (6,984,105)	\$ 10,647,742

The accompanying notes are an integral part of these unaudited consolidated interim financial statements.

**Consolidated Interim Statements of Cash Flows**

(Unaudited)

(U.S. Dollars)

<b>Cash Resources Provided By (Used In)</b>	<b>Three Month Period Ended 31 October</b>	
	<b>2018</b>	<b>2017</b>
<b>Operating Activities</b>		
Loss for the period	\$ (211,794)	\$ (450,508)
Items not affecting cash:		
Depreciation	69,557	-
Income tax	123,555	-
Foreign exchange	738	-
Loss on equity accounted investment	7,620	-
Amounts receivable and prepaids	(115,717)	(25,986)
Inventory	(159,095)	-
Trade payables and accrued liabilities	102,343	192,330
Due to related parties	(41,006)	(4,805)
	<u>(223,799)</u>	<u>(288,969)</u>
<b>Investing Activities</b>		
Investment in Nevada Medical Group, LLC	-	(92,674)
Investment in NMG Ohio, LLC	(30,000)	-
Purchase of property and equipment	(43,872)	-
	<u>(73,872)</u>	<u>(92,674)</u>
<b>Financing Activities</b>		
Subscription receipts	-	4,769,943
	<u>-</u>	<u>4,769,943</u>
Effect of exchange rate changes on cash	73,315	(73,728)
<b>Net Increase (Decrease) in Cash</b>	<b>(224,356)</b>	<b>4,314,572</b>
Cash– Beginning	324,837	366,584
<b>Cash– Ending</b>	<b>\$ 100,481</b>	<b>\$ 4,681,156</b>

**Supplemental Disclosures with Respect to Cash Flows (Note 9)**

The accompanying notes are an integral part of these unaudited consolidated interim financial statements.

**Body and Mind Inc.**

**Notes to Consolidated Interim Financial Statements**

(Unaudited)

**For the three months ended 31 October 2018**

*U.S. Dollars*

---

**1. Nature and Continuance of Operations**

Body and Mind Inc. (the “Company”) was incorporated on 5 November 1998 in the State of Delaware, USA. On 14 November 2017, the Company acquired Nevada Medical Group, LLC (“NMG”) and changed its name to Body and Mind Inc. The Company is now a supplier and grower of medical and recreational marijuana in the state of Nevada (Note 10).

These unaudited consolidated interim financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”). These unaudited consolidated interim financial statements do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the financial statements for the year ended 31 July 2018. The unaudited consolidated interim financial statements should be read in conjunction with the Company’s audited financial statements for the year ended 31 July 2018. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three months ended 31 October 2018 are not necessarily indicative of the results that may be expected for the year ending 31 July 2019.

These unaudited consolidated interim financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. At 31 October 2018, the Company had cash of \$100,481 (31 July 2018 – \$324,837) and a working capital deficit of \$1,133,314 (31 July 2018 –\$998,878).

Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive, or raise additional debt and/or equity capital. Management believes that the Company’s capital resources will not be adequate to continue operating and maintaining its business strategy for the next 12 months. If the Company is unable to raise additional capital in the near future, management expects that the Company will need to curtail operations, seek additional capital on less favourable terms and/or pursue other remedial measures.

These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

At 31 October 2018, the Company had incurred losses from activities to date. Although management is currently attempting to implement its business plan, and is seeking additional sources of equity or debt financing, there is no assurance these activities will be successful. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

**Principles of Consolidation**

These consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, DEP Nevada Inc. (“Dep Nevada”), incorporated in the State of Nevada on 10 August 2017, and NMG from the date of acquisition on 14 November 2017.

All inter-company transactions are eliminated upon consolidation.

**Body and Mind Inc.**

**Notes to Consolidated Interim Financial Statements**

(Unaudited)

For the three months ended 31 October 2018

U.S. Dollars

**2. Recent Accounting Pronouncements**

In February 2016, the FASB issued ASU No. 2016-02 (Topic 842) "Leases." Topic 842 supersedes the lease recognition requirements in Accounting Standards Codification ("ASC") Topic 840 "Leases." Under Topic 842, lessees are required to recognize assets and liabilities on the balance sheet for most leases and provide enhanced disclosures. Leases will continue to be classified as either finance or operating. Topic 842 is effective for annual reporting periods and interim periods within those years beginning after 15 December 2018. Early adoption by public entities is permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements, and there are certain optional practical expedients that an entity may elect to apply. Full retrospective application is prohibited. The Company is currently evaluating the impact that this new standard will have on its financial statements.

In June 2016, the FASB issued ASU No. 2016-13 "Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. ASU 2016-13 is effective for annual reporting periods, and interim periods within those years beginning after 15 December 2019. The Company does not anticipate this amendment to have a significant impact on the financial statements.

**3. Inventory**

	<u>31 October 2018</u>	<u>31 July 2018</u>
Raw materials	\$ 9,321	\$ 9,705
Work in progress	252,707	151,039
Finished goods	454,738	567,563
Consumables	395,746	225,110
<b>Total</b>	<u>\$ 1,112,512</u>	<u>\$ 953,417</u>

**4. Property and Equipment**

	<u>Office Equipment</u>	<u>Cultivation Equipment</u>	<u>Production Equipment</u>	<u>Kitchen Equipment</u>	<u>Vehicles</u>	<u>Vault Equipment</u>	<u>Leaseholder Improvements</u>	<u>Total</u>
<b>Cost:</b>								
Balance, 31 July 2018	\$ 24,586	\$ 435,109	\$ 261,957	\$ 27,694	\$ 38,717	\$ 1,644	\$ 1,993,928	\$ 2,783,635
Additions	1,739	6,138	1,326	-	-	-	34,669	43,872
Balance, 31 October 2018	<u>26,325</u>	<u>441,247</u>	<u>263,283</u>	<u>27,694</u>	<u>38,717</u>	<u>1,644</u>	<u>2,028,597</u>	<u>2,827,507</u>
<b>Accumulated Depreciation:</b>								
Balance, 31 July 2018	3,177	41,169	25,446	2,554	5,500	228	89,663	167,737
Depreciation	1,187	18,145	10,604	1,121	1,954	81	36,465	69,557
Balance, 31 October 2018	<u>4,364</u>	<u>59,314</u>	<u>36,050</u>	<u>3,675</u>	<u>7,454</u>	<u>309</u>	<u>126,128</u>	<u>237,294</u>
<b>Net Book Value:</b>								
As at 31 July 2018	<u>21,409</u>	<u>393,940</u>	<u>236,511</u>	<u>25,140</u>	<u>33,217</u>	<u>1,416</u>	<u>1,904,265</u>	<u>2,615,898</u>
As at 31 October 2018	<u>\$ 21,961</u>	<u>\$ 381,933</u>	<u>\$ 227,233</u>	<u>\$ 24,019</u>	<u>\$ 31,263</u>	<u>\$ 1,335</u>	<u>\$ 1,902,469</u>	<u>\$2,590,213</u>



**Body and Mind Inc.**  
**Notes to Consolidated Interim Financial Statements**  
(Unaudited)  
**For the three months ended 31 October 2018**  
*U.S. Dollars*

---

**5. Related Party Balances and Transactions**

In addition to those disclosed elsewhere in these consolidated financial statements, related party transactions for the three month period ended 31 October 2018 and 2017 are as follows:

- a) During the three months ended 31 October 2018, accounting fees of \$6,908 (2017 - \$3,600) and management fees of \$Nil (2017 - \$7,200) were paid/accrued to a company controlled by the former Chief Financial Officer and a director of the Company.
- b) During the three months ended 31 October 2018, management fees of \$7,676 (2017 - \$Nil) were paid/accrued to companies related to the Chief Executive Officer of the Company.
- c) During the three months ended 31 October 2018, management fees of \$33,654 (2017 - \$Nil) were paid/accrued to a company controlled by a director of the Company.
- d) During the three months ended 31 October 2018, management fees of \$11,514 (2017 - \$12,000) were paid/accrued to a company controlled by the Chief Financial Officer of the Company.
- e) During the three months ended 31 October 2018, management fees of \$Nil (2017 - \$2,740) were paid/accrued to a former Chief Executive Officer of the Company.
- f) As at 31 October 2018, the Company owed \$8,877 (31 July 2018 - \$17,028) to the Chief Executive Officer of the Company and a company controlled by him.
- g) As at 31 October 2018, the Company owed \$Nil (31 July 2018 - \$4,033) to the Chief Financial Officer of the Company
- h) As at 31 October 2018, the Company owed \$1,198 (31 July 2018 - \$1,210) to a director of the Company and a company controlled by him.
- i) As at 31 October 2018, the Company owed \$Nil (31 July 2018 - \$28,810) to a director of the Company and a company controlled by him.

The above amounts owing to related parties are unsecured, non-interest bearing and are due on demand.

In addition, there are amounts owing to related parties resulting from the purchase of NMG (Note 6).

**6. Promissory Notes**

In connection with the Acquisition of NMG, on 14 November 2017, the Company issued a promissory notes in the amount of \$2,175,000 to NMG Members (Note 10).

As these promissory notes are non-interest bearing, they were discounted to a present value of \$1,887,863 at a rate of 12%.

Both promissory notes are non-interest bearing, secured by the assets of the Company, and due 14 February 2019 or within 30 days from the date of the Company completes a financing of at least \$500,000. Any unpaid amounts at maturity will bear interest at a rate of 10% per annum.

**Body and Mind Inc.**  
**Notes to Consolidated Interim Financial Statements**  
(Unaudited)  
**For the three months ended 31 October 2018**  
*U.S. Dollars*

---

**6. Promissory Notes – Continued**

At 31 July 2018, the promissory notes were accreted to their face value as it was estimated that repayment would occur imminently due to the Company's fund raising initiatives (Note 13).

	<u>31 October 2018</u>	<u>31 July 2018</u>
Balance, beginning	\$ 2,175,000	\$ -
Issuance of promissory notes (Note 12)	-	1,887,277
Accretion expense	-	277,219
Foreign exchange adjustment	-	10,504
<b>Balance, ending</b>	<u>\$ 2,175,000</u>	<u>\$ 2,175,000</u>

**7. Capital Stock**

The Company's authorized share capital comprises 900,000,000 Common Shares, with a \$0.0001 par value per share.

On 13 March 2017, a total of 150,000 Class A preferred shares were converted into 500,000 common shares of the Company. On 8 May 2017, the remaining 2,325,500 Class A preferred shares were converted into 7,751,765 common shares of the Company. In connection with the Acquisition, on 14 November 2017, the Company eliminated its authorized Class A Preferred share class and completed a consolidation of its common shares on the basis of three (3) pre-consolidation common shares to one (1) post-consolidation common share. Unless otherwise noted, all figures in the financial statements are retroactively adjusted to reflect the consolidation (Note 10).

On 15 August 2017 and 16 August 2017, the Company closed the first two of four tranches of a non-brokered private placement and issued 8,276,294 Subscription Receipts (defined below) at a price of \$0.52 (CAD\$0.66) per Subscription Receipt for aggregate gross proceeds of \$4,270,017 (CAD\$5,462,354) (Note 10).

On 31 October 2017, the Company closed a third tranche of a non-brokered private placement and issued 757,666 Subscription Receipts at a price of \$0.52 (CAD\$0.66) per Subscription Receipt for aggregate gross proceeds of \$390,822 (CAD\$500,060) (Note 10).

On 1 November 2017, the Company closed a fourth and final tranche of a non-brokered private placement and issued 68,181 Subscription Receipts at a price of \$0.52 (CAD\$0.66) per Subscription Receipt for aggregate gross proceeds of \$35,169 (CAD\$45,000) (Note 10).

On 14 November 2017, the Company issued a total of 18,827,000 common shares valued at \$6,337,365 in connection with the Acquisition of NMG (Note 10). The Company is obligated to issue 423,000 common shares, which have a fair value of \$135,202 (Note 10). On 14 November 2017, a total of 9,102,141 Subscription Receipts converted to 9,102,141 common shares and 9,102,141 share purchase warrants exercisable at CAD \$0.66 or CAD\$0.90 for a period of 24 months pursuant to the closing of the Acquisition of NMG (Note 10). The Company issued a total of 367,286 brokers' warrants with a fair value of \$62,357 (CAD\$78,122) in connection with these financings. The brokers' warrants are exercisable at CAD\$0.90 for a period of 24 months. The Company incurred other share issuance costs of \$219,459 (CAD\$279,352) in relation to this private placement.

**Body and Mind Inc.**

**Notes to Consolidated Interim Financial Statements**

(Unaudited)

**For the three months ended 31 October 2018**

*U.S. Dollars*

---

**7. Capital Stock – Continued**

On 1 December 2017, the Company closed a non-brokered private placement of 637,393 units at a price of \$0.52 (CAD\$0.66) per unit for aggregate gross proceeds of \$330,486 (CAD\$420,680). Each unit consists of one common share and one share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the Company at a price of CAD\$0.90 per warrant for a period of 24 months from the closing.

On 16 May 2018, the Company issued 70,500 previously escrowed shares with a fair value of \$31,935 to Toro Pacific Management Inc. in connection with the acquisition of NMG (Note 10).

**Stock options**

The Company previously approved an incentive stock option plan (the “Plan”), pursuant to which the Company may grant stock options up to an aggregate of 10% of the issued and outstanding common shares in the capital of the Company from time to time.

On 24 November 2017, the Company issued an aggregate of 3,850,000 stock options in accordance with the Company’s stock option plan at an exercise price of CDN\$0.66 per share for a five year term expiring 24 November 2022. The options were granted to officers, directors and consultants of the Company.

The fair value of the stock options was calculated to be \$726,578 (CAD\$922,403) using the Black-Scholes Option Pricing Model using the following assumptions:

Expected life of the options	5 years
Expected volatility	198%
Expected dividend yield	0%
Risk-free interest rate	1.63%

On 6 June 2018, the Company issued 175,000 stock options in accordance with the Company’s stock option plan at an exercise price of CDN\$0.47 per share for a five year term expiring 6 June 2023. The options were granted to a consultant of the Company.

The fair value of the stock options was calculated to be \$63,101 (CAD\$81,129) using the Black-Scholes Option Pricing Model using the following assumptions:

Expected life of the options	5 years
Expected volatility	262%
Expected dividend yield	0%
Risk-free interest rate	2.16%

**Body and Mind Inc.**  
**Notes to Consolidated Interim Financial Statements**  
(Unaudited)  
**For the three months ended 31 October 2018**  
*U.S. Dollars*

7. **Capital Stock – Continued**

	31 October 2018		31 July 2018	
	Number of options	Exercise Price	Number of options	Exercise Price
Opening balance	4,025,000	CAD\$0.65	-	-
Options granted	-	-	4,025,000	CAD\$0.65
Closing balance	4,025,000	CAD\$0.65	4,025,000	CAD\$0.65

**Share purchase warrants and brokers' warrants**

	31 October 2018		31 July 2018	
	Number of warrants	Exercise Price	Number of warrants	Exercise Price
Opening balance	10,106,820	CAD\$0.89	-	-
Warrants issued	-	-	10,106,820	CAD\$0.89
Closing balance	10,106,820	CAD\$0.89	10,106,820	CAD\$0.89

As at 31 October 2018, the following warrants are outstanding:

Number of warrants outstanding and exercisable	Exercise price	Expiry dates
248,350	CAD\$0.66	15 August 2019
58,324	CAD\$0.66	16 August 2019
60,612	CAD\$0.66	3 November 2019
9,102,141	CAD\$0.90	14 November 2019
637,393	CAD\$0.90	1 December 2019
<u>10,106,820</u>		

8. **Segmented Information**

The Company's activities are all in the one industry segment of medical and recreational marijuana. All of the Company's revenue generating activities and capital assets relate to this segment and are located in the USA.

9. **Supplemental Disclosures with Respect to Cash Flows**

	Three Month Period Ended 31 October	
	2018	2017
Cash paid during the period for interest	\$ -	\$ -
Cash paid during the period for income taxes	\$ -	\$ -

**Body and Mind Inc.**

**Notes to Consolidated Interim Financial Statements**

(Unaudited)

**For the three months ended 31 October 2018**

*U.S. Dollars*

---

**10. Business Acquisition**

On 15 May 2017, the Company entered into an assignment and novation agreement (the "Assignment Agreement") with Toro Pacific Management Inc. (the "Transferor") pursuant to which the Transferor assigned a letter of intent (the "LOI") effective 12 May 2017 to the Company in accordance with its terms. The Assignment Agreement and the LOI contemplated a business combination transaction (the "Acquisition") to acquire all of the issued and outstanding securities of NMG, an arm's length Nevada-based licensed producer of medical marijuana.

As consideration for the Assignment Agreement, the Company will issue to the Transferor 1,000,000 common shares of the Company. On November 13, 2017, the Assignment Agreement was amended, whereby the Company would issue the 1,000,000 common shares as follows:

470,000 common shares to Benjamin Rutledge upon closing of the Acquisition (issued);  
60,000 common shares to Chris Hunt upon closing of the Acquisition (issued);  
470,000 common shares to the Transferor according to the following schedule:  
1/10 of the Transferor's shares upon closing of the Acquisition (issued);  
1/6 of the remaining Transferor's shares 6 months after closing the Acquisition (issued);  
1/5 of the remaining Transferor's shares 12 months after closing the Acquisition;  
1/4 of the remaining Transferor's shares 18 months after closing the Acquisition;  
1/3 of the remaining Transferor's shares 24 months after closing the Acquisition;  
1/2 of the remaining Transferor's shares 30 months after closing the Acquisition; and  
of the remaining Transferor's shares 36 months after closing the Acquisition.

The remaining 423,000 shares to be issued to the Transferor are over the 36 month period included in equity as shares to be issued with a total fair value of \$135,202 (Note 9).

On 14 September 2017, the Company and Dep Nevada entered into a definitive agreement (the "Share Exchange Agreement") with NMG. Pursuant to the Share Exchange Agreement, Dep Nevada acquired all of the issued and outstanding securities of NMG in exchange for the issuance of the Company's common shares and certain cash and other non-cash consideration (the "Acquisition").

The Company completed a concurrent financing consisting of 9,102,141 subscription receipts of the Company (the "Subscription Receipts"), at an issue price of CAD\$0.66 per Subscription Receipt, with each Subscription Receipt being automatically converted, at no additional cost to the subscriber, upon the completion of the Acquisition for one common share and one share purchase warrant exercisable at a price of CAD\$0.90 for a period of 24 months from the date of issuance. Each warrant is subject to acceleration provisions following the six-month anniversary of the date of closing, if the closing trading price of the common shares is equal to or greater than CAD\$1.20 for seven consecutive trading days, at which time the Company may accelerate the expiry date of the warrants by issuing a press release announcing the reduced warrant term whereupon the warrant will expire 21 calendar days after the date of such press release. These Subscription Receipts were recognized as liability on initial receipt. During the year ended 31 July, 2018, the Acquisition closed and the shares were issued; therefore the Subscription Receipts were reclassified from liability to equity on conversion to common shares.

On 14 November 2017, the Company closed the Acquisition, and acquired all of the issued and outstanding membership units of NMG (the "Units"). In consideration for the Units, the Company issued to the NMG Members an aggregate of 16,000,000 common shares with a fair value of \$5,386,155 as well as a cash payment of \$2,309,000 pro rata amongst the NMG members and promissory notes to the NMG members in the aggregate amount of \$2,175,000. The Company also issued 2,037,879 common shares to TI Nevada with a fair value of \$685,788, 212,121 common shares to Charles Fox with a fair value of \$71,383, 47,000 common shares to Toro Pacific Management Inc. with a fair value of \$15,816, 60,000 common shares to Chris Hunt with a fair value of \$20,192, and 470,000 common shares to Benjamin Rutledge with a fair value of \$159,114 in connection with the Acquisition.

**Body and Mind Inc.**  
**Notes to Consolidated Interim Financial Statements**  
(Unaudited)  
**For the three months ended 31 October 2018**  
*U.S. Dollars*

---

**10. Business Acquisition – Continued**

The Company has an obligation to issue a further 423,000 common shares to Toro Pacific Management Inc., which had a fair value of \$135,202 on the date of acquisition.

The Company recognized \$330,324 in transaction costs in connection with the shares issued to non-NMG members. The promissory notes totalling \$2,175,000 were discounted to a present value of \$1,887,277 (Note 6). In connection with the closing of the Acquisition, the net proceeds of the Company's private placements of Subscription Receipts in support of the Acquisition was released to the Company from escrow. Immediately prior to closing of the Acquisition, the Company completed a consolidation of its common shares on the basis of three (3) pre-consolidation common shares to one (1) post-consolidation common share, as well a name change, changing the name of the Company from Deploy Technologies, Inc. to Body and Mind Inc. The Company eliminated its authorized Class A Preferred shares (Note 7).

As a result of the acquisition of NMG, the Company changed its business focus to growing and supplying medical and recreational marijuana in the state of Nevada. The acquisition of NMG was accounted for as a business combination, in which the assets acquired and the liabilities assumed are recorded at their estimated fair values. The allocation of the purchase consideration is as follows:

<b>Purchase consideration</b>	
Share considerations	\$ 6,143,326
Cash considerations	2,309,000
Promissory notes issued	1,887,277
<b>TOTAL</b>	<b><u>10,339,603</u></b>
<b>Assets acquired:</b>	
Cash	260,842
Amounts receivable	253,697
Prepaid expenses	44,552
Inventory	498,680
Property and equipment	1,951,696
Brand	247,000
Licenses	7,925,000
<b>Liabilities assumed:</b>	
Trade payable and accrued liabilities	(367,385)
Loans payable	(250,000)
Deferred tax liability	(2,860,200)
<b>Net assets acquired</b>	<b>7,703,882</b>
Goodwill	2,635,721
<b>TOTAL</b>	<b><u>\$ 10,339,603</u></b>

Goodwill recognized comprises the assembled workforce and their knowledge with respect to NMG, regulatory affairs and the cannabis industry; and expected revenue growth and future market development with legalization of recreational cannabis in Nevada.

**Body and Mind Inc.**

**Notes to Consolidated Interim Financial Statements**

(Unaudited)

**For the three months ended 31 October 2018**

*U.S. Dollars*

---

**11. Commitments and Others**

- a) On 11 November 2014, NMG entered into a five year lease for its premises. The Company has five options to extend the lease and each option is for five years. The monthly rent was \$12,500, increased to \$15,000 on 1 January 2018. The guaranteed minimum monthly rent is subject to a 3% increase on each anniversary date of the lease.
- b) On 14 November 2017, the Company entered into the following consulting agreements:
  - i. \$16,667 per month to TI Nevada for a term of three years; and
  - ii. CAD\$10,000 per month to Toro Pacific Management Inc., which is controlled by an officer of the Company.
- c) On 30 October 2018 the Company entered into a strategic investment agreement (the "Investment Agreement") with Australis Capital Inc. ("Australis") (Note 15). Pursuant to the terms of the Investment Agreement, Australis will acquire (i) 16,000,000 units (the "Units") of the Company, each comprised of one common share (a "Common Share") and one common share purchase warrant (a "Warrant") of the Company, at a purchase price of CAD\$0.40 per Unit for gross proceeds of CAD\$6,400,000, and (ii) CAD\$1,600,000 principal amount 8% unsecured convertible debentures (the "Debentures") of the Company maturing two years following the date of issue (collectively, the "Financing"). Each Warrant is exercisable to acquire one Common Share of the Company at an exercise price of CAD\$0.50 per share for a period of two years, subject to adjustment and acceleration in certain circumstances.

The Debentures will bear interest from the date of issuance (the "Issue Date") at a rate of 8% per annum, calculated and payable semi-annually, in arrears. Repayment of the then outstanding principal amount of the Debentures, together with any accrued and unpaid interest thereon, is to be made on or prior to the date that is two years from the Issue Date (the "Maturity Date"). The Debentures are convertible at the option of Australis into Common Shares at a conversion price equal to CAD\$0.55 per Common Share up to the Maturity Date, subject to adjustment and acceleration in certain circumstances.

Under the terms of the Investment Agreement, the parties have agreed to negotiate in good faith a license agreement pursuant to which the Company will grant Australis an exclusive and assignable license to use the BaM brand outside of the United States of America on commercially reasonable terms.

In addition, the Company will enter into a commercial advisory agreement with Australis Capital (Nevada) Inc. ("Australis Nevada"), a wholly-owned subsidiary of Australis, pursuant to which Australis Nevada will provide advisory and consulting services to the Company for a term ending on the date that is the earlier of: (i) five years following the closing of the transactions contemplated by the Investment Agreement, and (ii) the date Australis no longer holds 10% or more of the issued and outstanding Common Shares. Subject to certain exceptions, Australis will be entitled to maintain its' pro rata interest in the Company until such time as it no longer holds 10% or more of the issued and outstanding Common Shares.

Subject to applicable laws and the rules of the Canadian Securities Exchange, for as long as Australis owns at least 10% of the issued and outstanding Common Shares, Australis will be entitled to nominate one director for election to the Board of Directors of the Company (the "Board"). If Australis exercises all of the Warrants and converts all of the Debentures purchased in the Financing, Australis will be entitled to nominate a second director for election to the Board.

**Body and Mind Inc.**

**Notes to Consolidated Interim Financial Statements**

(Unaudited)

**For the three months ended 31 October 2018**

*U.S. Dollars*

---

**12. Investment in NMG Ohio LLC**

On 7 June 2018, the Company acquired a 30% interest in NMG Ohio LLC ("NMG Ohio"). As at 31 October 2018, the Company had an investment of \$99,242 (31 July 2018 - \$77,600) in NMG Ohio. The investment is accounted for using the equity method of accounting.

**13. Subsequent Events**

On 2 November 2018, the Company executed the Investment Agreement and completed the sale of securities pursuant to the Investment Agreement (Note 11).

On 29 November 2018, the Company and Australis Capital Inc. announced an investment by the Company into Green Light District Holdings, Inc. ("GLDH") by way of a \$5,200,000 senior secured convertible note at a rate equal to 20% per annum. The note is convertible into 89.75% of the shares of GLDH at the option of the Company. In addition, the Company has an agreement to issue additional consideration to David Barakett totalling \$6,297,580 payable in common shares of the Company at a price of CAD\$0.7439 upon meeting certain milestones. The price was calculated using a 5-day volume weighted average price as of 28 November 2018.

Australis Capital Inc. provided the Company a two-year USD \$4,000,000 loan ("AUSA Debt Financing") by way of a senior secured note bearing an interest rate of 15% per annum. The terms require semi-annual interest payments unless the Company elects to accrue the interest by adding it to the principal amount of the debt facility. The Company will maintain prepayment rights at any time, in any amount, unless it is within the first year in which case the Company will be required to pay a 5% prepayment penalty on the amount repaid. Additionally, Australis Capital Inc. exercised USD \$1.2m in warrants they held in the Company at an exercise price of CAD \$0.50, which equated to 3,206,160 common shares.

The Company paid a finance fee to Australis Capital Inc. in the amount of 1,105,083 common shares of the Company at a deemed price of CAD \$0.72 per share. The Company also paid a financial advisory fee of CAD \$150,000.

On 11 December 2018, the Company granted an aggregate of 2,050,000 stock options to newly appointed management personnel, in addition to current directors, officers, employees and consultants of the Company, at an exercise price of CAD\$0.57 per share for a five year term expiring 10 December 2023.



## ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The terms "BAM", "Company", "we", "our", and "us" refer to Body and Mind Inc. unless the context suggests otherwise.

### FORWARD-LOOKING STATEMENTS

*This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. All statements, other than statements of historical facts, included in this Form 10-Q that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These forward-looking statements are based on assumptions which we believe are reasonable based on current expectations and projections about future events and industry conditions and trends affecting our business. However, whether actual results and developments will conform to our expectations and predictions is subject to a number of risks and uncertainties that, among other things, could cause actual results to differ materially from those contained in the forward-looking statements, including without limitation the Risk Factors set forth in our Form 10 including statements with respect to the following:*

- *our failure to obtain additional financing;*
- *our inability to continue as a going concern;*
- *the unique difficulties and uncertainties inherent in the business;*
- *local and multi-national economic and political conditions, and*
- *our common stock.*

### General

We are a reporting issuer in British Columbia and Ontario, and have our shares of common stock listed on the Canadian Securities Exchange under the symbol "BAMM", with a head office located at 750 – 1095 West Pender Street, Vancouver, British Columbia, Canada V6E 2M6.

We were originally incorporated on November 5, 1998 in the State of Delaware under the name Concept Development Group, Inc. In May 2004, we acquired 100% of Kaleidoscope Venture Capital, Inc. (formerly Vocalscape Networks, Inc.) and changed our name to Vocalscape, Inc. In November 2005, we changed our name to Nevstar Precious Metals Inc. In September 2008, we changed our name to Deploy Technologies Inc. ("**Deploy Tech**") and effective November 13, 2017, we changed our name to Body and Mind, Inc. ("**Body and Mind**").

On September 15, 2010, we incorporated a wholly-owned subsidiary, Deploy Acquisition Corp. ("**Deploy**") under the laws of the State of Nevada, USA. On September 17, 2010, Deploy completed a merger with Deploy Tech, its former parent company, pursuant to which Deploy was the surviving corporation and assumed all the assets, obligations and commitments of Deploy Tech. Upon the completion of the merger Deploy assumed the name "Deploy Technologies Inc." and all of the issued and outstanding common stock of Deploy Tech was automatically converted into and became Deploy's issued and outstanding common stock. On May 10, 2011, we registered as an extra-provincial company in British Columbia and on September 30, 2011, we filed a certificate of amendment with the Nevada Secretary of State to designate 2,900,000 shares of our authorized capital stock as Class A Preferred Shares (the "**Preferred Shares**"). On September 2, 2014, we filed a certificate of amendment with the Nevada Secretary of State increasing the authorized Preferred Shares from 2,900,000 shares to 20,000,000 shares. On November 11, 2014, we filed a certificate of change with the Nevada Secretary of State whereby we reverse split our authorized as well as the issued and outstanding shares of common stock (the "Common Shares") on the basis of one (1) new share for ten (10) old shares which resulted in a reduction of our authorized capital from 100,000,000 Common Shares to 10,000,000 Common Shares and our issued and outstanding Common Shares decreasing from 23,130,209 Common Shares to approximately 2,313,021 Common Shares. On April 11, 2017, we filed a certificate of amendment with the Nevada Secretary of State to increase the authorized capital from 10,000,000 Common Shares to 900,000,000 Common Shares.

On August 10, 2017, we incorporated a wholly-owned subsidiary, Dep Nevada Inc. (“**DEP**”). On September 14, 2017, we, with DEP, entered into a definitive agreement (the “**Share Exchange Agreement**”) with Nevada Medical Group, LLC (“**NMG**”), an arm’s length party, to carry out the business combination transaction initially announced on May 17, 2017, following the signing of the letter of intent between Toro Pacific Management Inc. (“**Toro**”) and NMG (the “**Letter of Intent**”), which was assigned to us pursuant to an assignment and novation agreement among Toro, NMG, and us dated effective May 12, 2017 (the “**Assignment Agreement**”). Pursuant to the Assignment Agreement, Toro received 470,000 of our Common Shares. Pursuant to the Share Exchange Agreement, we changed our name to “Body and Mind, Inc.” effective on November 14, 2017 by filing a certificate of amendment with the Nevada Secretary of State and at the same time we cancelled our entire authorized class of Preferred Shares. In addition, on November 14, 2017, we filed a certificate of change with the Nevada Secretary of State whereby we reverse split our issued and outstanding Common Shares on the basis of one (1) new share for three (3) old shares (the “**Consolidation**”) which resulted in there being 28,239,876 Common Shares issued and outstanding post-Consolidation. DEP, our wholly-owned subsidiary, acquired all of the issued and outstanding securities of NMG in exchange for the issuance of our Common Shares on a post-consolidation basis and certain cash and other non-cash consideration, as further described below (the “**Acquisition**”). Completion of the Acquisition resulted in a fundamental change under the policies of the Canadian Securities Exchange (the “**CSE**”). Subsequent to completion of the Acquisition, we filed articles of exchange with the Nevada Secretary of State.

We completed a concurrent equity financing to raise aggregate gross proceeds of CAD\$6,007,429.89 through the issuance of subscription receipts (the “**Subscription Receipts**”) with each Subscription Receipt convertible into one pre-Consolidation Common Share and one common share purchase warrant (each a “**Warrant**”) of Body and Mind, at a price of CAD\$0.22 per Subscription Receipt (the “**Concurrent Financing**”). Each Warrant is exercisable by the holder at a price of CAD \$0.30 for a period of 24 months from the date of issuance. Each Warrant is subject to acceleration provisions following May 14, 2018, if the closing trading price of the Common Shares is equal to or greater than CAD\$1.20 for seven consecutive trading days, at which time we may accelerate the expiry date of the Warrants by issuing a press release announcing the reduced warrant term whereupon the Warrants will expire 21 calendar days after the date of such press release.

In consideration for all of the issued securities of NMG, the NMG securityholders (collectively, the “**NMG Members**”) received, on a pro rata basis, (a) 16,000,000 post-Consolidation Common Shares (the “**Payment Shares**”) at a deemed price of CAD\$0.66 per share (the “**Share Exchange**”), (b) \$2,000,000 cash, and (c) five non-interest bearing promissory note for an aggregate amount of \$2,000,000 (the “**Promissory Notes**”) issued as follows: \$450,000 to MBK Investments, LLC, \$450,000 to the Rozok Family Trust, \$490,000 to KAJ Universal Real Estate Investments, LLC, \$120,000 to NV Trees, LLC, and \$490,000 to SW Fort Apache, LLC. The Promissory Notes were secured by a senior priority security interest in all of our assets, to be paid at the earlier of fifteen (15) months from the closing date of the Acquisition or, if an equity or debt financing subsequent to the Concurrent Financing is closed in an aggregate amount of not less than \$5,000,000, then within 30 days of the closing date of such subsequent financing. We assumed NMG’s obligations pursuant to a loan in the amount of \$400,000, payable to TI Nevada, LLC, (“**TI Nevada**”) of which \$225,000 was paid on the Closing Date (as defined below) and the remaining \$175,000, which was secured by a senior priority security interest in all of our assets, will be paid within 15 months of the Closing Date. Furthermore, we reimbursed NMG (\$84,000) for expenditures incurred prior to the Closing Date which were related to the acquisition of production equipment.

## **Plan of Operations**

### ***Past business of Deploy***

We were a development stage company engaged in designing and developing technologies and products for the management of truck fleets by companies in the freight haulage, waste haulage, mining, industrial operations and manufacturing, military and law enforcement industries.

We identified our proprietary technology and primary product by the name “Fleet Data Management & Weigh System”. The principal and unique feature of the Fleet Data Management & Weigh System enables operators of heavy industrial hydraulic lifting equipment to weigh cargo “on-the-fly” during the process of loading carrier vehicles. The load weight of trucks is important information for several purposes, including billing, compliance with highway and safety regulations and loading within capacity specifications.

We designed and developed the Fleet Data Management & Weigh System to provide this information, as well as much more, on a real-time basis. The Fleet Data Management & Weigh System is capable of providing such information for in-cab entry and can deliver the information by wireless communication to operations centers, billing departments and for archival purposes, in order to meet the needs of any fleet operator.

Following the 2008 acquisition by our predecessor entity of the on-the-fly weigh system technology from Trepped Enterprises Inc., we devoted much of our time to engineering; circuit board design and testing; firmware and software development and testing; adding components and features; hardware selection; and improving, testing and packaging the Fleet Data Management & Weigh System. Upon the completion of our merger with Deploy Tech, we acquired the rights to both the technology and products that comprise the system by virtue of being the surviving corporation.

We developed a final prototype of the products that comprise our Fleet Data Management & Weigh System. We have tested both prototype packages on various types of vehicles. We have experienced delays due to lack of required funding which resulted in less attention on sales and marketing than expected.

Due to the large number of different vehicles and vehicle models that contain variations in parts, our system had to be tested on each variation of a vehicle before it can be sold to customers to ensure that it is properly calibrated for that specific vehicle. This significantly increases our testing and sales timelines.

Throughout our 2014 fiscal year, our management was focused on sales of our products as well as raising capital required to achieve our sales and marketing goals. We were not successful in raising required capital to hire sales and marketing staff or launch a sales and marketing campaign and therefore restructured the company to be more attractive to the investment community.

Although a lack of funding caused delays in sales and marketing efforts, we were able to remain current in our reporting obligations, including the year-end requirements to file our audited financial statements, MD&A and annual listing statement.

Throughout our previous three years, we had developed and patented and had been selling our Fleet Data Management & Weigh System and prepared the Company for commercialization of our product line. We remain the owner of Patent # 2798525 which is titled as "*Load-Measuring, Fleet Asset Tracking and Data Management System for Load-Lifting Vehicles.*" While we continue to own and maintain this patent, our focus has changed to the business of cultivating and producing medical and recreational marijuana as further described in the "Description of Business" below. We anticipate selling our patent in the foreseeable future and do not anticipate allocating any current or future resources to our prior business.

### **Description of Business**

NMG was organized as a limited liability company under the laws of the State of Nevada on March 3, 2014. NMG was an early applicant in Nevada in 2014 and was awarded one of the first state medical licenses for both cultivation and production of marijuana. NMG has been a licensed producer and cultivator of cannabis products since it was issued its first cultivation license on November 5, 2015 and production license on December 10, 2015. On July 1, 2017 NMG was awarded an additional state recreational cultivation and production license. NMG operates under its marquee brand name of Body & Mind Inc. ("**BaM**") and produces flower, oil extracts and edibles and are available for sale in dispensaries in Nevada.

NMG anticipates an increase in demand due to the recently approved "Adult Use" licensing in the State of Nevada that began in July 2017. NMG has several growth initiatives underway including new product introductions, product licensing, third party extraction, out-of-State licensing, and acquisitions.

[Table of Contents](#)

**Results of Operations for the three month periods ended October 31, 2018 and 2017**

The following table sets forth our results of operations for the three month periods ended October 31, 2018 and 2017:

	October 31, 2018	October 31, 2017
	\$	\$
Sales	1,325,978	-
Cost of Sales	(869,040)	-
Gross Margin	456,938	-
General and Administrative Expenses	(466,051)	(376,717)
Foreign Currency Translation Adjustment	73,315	(73,728)
Comprehensive (Loss)	(138,479)	(524,236)
Basic and Diluted Income (Loss) Per Share	0.00	(0.02)

Revenues

For the three month period ended October 31, 2018 we had total sales of \$1,325,978 and cost of sales of \$869,040 for a gross margin of \$456,938 compared to the three month period ended October 31, 2017 where we did not generate any revenues. During the three months ended October 31, 2018, the Company recorded product sales as follows:

Revenues – By Product	Three months ended October 31, 2018	
	\$	%
Flower	619,848	47
Concentrates	398,248	30
Edibles	90,413	7
Pre-rolled	217,469	16
Total	1,325,978	100

The Company's revenue generating products, being flower, concentrates, edibles and pre-rolled products, are expected to have relatively consistent revenues for the foreseeable future.

Operating Expenses

For the three month period ended October 31, 2018 ("Q1 2019"), operating expenses totaled \$466,061 compared with \$376,717 for the three month period ended October 31, 2017 ("Q1 2018"). During Q1 2019 the Company incurred the following significant expenses: \$78,381 (Q1 2018 - \$226,733) in accounting and legal fees, \$22,238 (Q1 2018 - \$Nil) for insurance, \$52,844 (Q1 2018 - \$21,940) in management fees, \$85,092 (Q1 2018 - \$62,162) in office and miscellaneous expenses, \$18,362 (Q1 2018 - \$Nil) in rent expenses and \$194,175 (Q1 2018 - \$Nil) for salaries and wages. In Q1 2018 the Company did not have any cannabis operations and is the reason the Q1 2018 general and administrative expenses were significantly lower than in Q1 2019.

Gross profit margin for Q1 2019 was \$456,938 (Q1 2018 - \$Nil) which represented a gross profit margin percentage of 34%. The Company did not report any revenues in comparative Q1 2018. The Company's gross margin percentage for the year ended July 31, 2018 was 44%. The primary reason the gross margin percentage decreased in Q1 2019 compared to the July 31, 2018 year-end gross profit margin percentage related to the hiring of approximately 11 new staff personnel throughout the three month period.

Other Items

During Q1 2019, other items accounted for \$79,126 in other income compared to \$73,791 in other expenses for Q1 2018. The significant components in other items primarily relates to foreign exchange income of \$71,554 in Q1 2019 compared to foreign exchange expense of \$72,903 in Q1 2018. Additionally, in Q1 2019, the Company recorded \$123,555 (Q1 2018 - \$Nil) in income tax expense.

Net Income (Loss)

Net loss for Q1 2019 totaled \$211,794 compared with a net loss of \$450,508 for Q1 2018. The decrease in net loss of \$238,714 between Q1 2019 and Q1 2018 was primarily a result from the sales generated from our products in Q1 2019. The Company had no revenues in Q1 2018.

Other Comprehensive Income (Loss)

We recorded a translation income adjustment of \$73,315 in Q1 2019 compared to a translation loss adjustment of \$73,728 in Q1 2018. The amounts are included in the statement of operations as other comprehensive gain (loss) for the respective periods.

**Liquidity and Capital Resources**

Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation.

The following table sets out our cash and working capital as of October 31, 2018:

	<b>As of October 31, 2018</b>
	(unaudited)
Cash reserves	\$ 100,481
Working capital (deficit)	\$ (1,133,314)

The Company's working capital deficit worsened during the three months ended October 31, 2018 as the Company incurred additional expenses to improve the production facility in Nevada, as well as investing in NMG Ohio, LLC.

On October 30, 2018, the Company entered into a strategic investment agreement (the "**Investment Agreement**") with Australis Capital Inc. ("**Australis**"). Pursuant to the terms of the Investment Agreement, Australis will acquire (i) 16,000,000 units (the "Units") of BaM, each comprised of one common share (a "Common Share") and one common share purchase warrant (a "Warrant") of the Company, at a purchase price of CAD\$0.40 per Unit for gross proceeds of CAD\$6,400,000, and (ii) CAD\$1,600,000 principal amount 8% unsecured convertible debentures (the "Debentures") of the Company maturing two years following the date of issue (collectively, the "Financing"). Each Warrant is exercisable to acquire one Common Share of the Company at an exercise price of CAD\$0.50 per share for a period of two years, subject to adjustment and acceleration in certain circumstances.

The Debentures will bear interest from the date of issuance (the "**Issue Date**") at a rate of 8% per annum, calculated and payable semi-annually, in arrears. Repayment of the then outstanding principal amount of the Debentures, together with any accrued and unpaid interest thereon, is to be made on or prior to the date that is two years from the Issue Date (the "**Maturity Date**"). The Debentures are convertible at the option of Australis into Common Shares at a conversion price equal to CAD\$0.55 per Common Share up to the Maturity Date, subject to adjustment and acceleration in certain circumstances.

Under the terms of the Investment Agreement, the parties have agreed to negotiate in good faith a license agreement pursuant to which the Company will grant Australis an exclusive and assignable license to use the BaM brand outside of the United States of America on commercially reasonable terms.

In addition, the Company will enter into a commercial advisory agreement with Australis Capital (Nevada) Inc. (“**Australis Nevada**”), a wholly-owned subsidiary of Australis, pursuant to which Australis Nevada will provide advisory and consulting services to the Company for a term ending on the date that is the earlier of: (i) five years following the closing of the transactions contemplated by the Investment Agreement, and (ii) the date Australis no longer holds 10% or more of the issued and outstanding Common Shares. Subject to certain exceptions, Australis will be entitled to maintain its’ pro rata interest in the Company until such time as it no longer holds 10% or more of the issued and outstanding Common Shares.

Subject to applicable laws and the rules of the CSE, for as long as Australis owns at least 10% of the issued and outstanding Common Shares, Australis will be entitled to nominate one director for election to the Board of Directors of the Company (the “**Board**”). If Australis exercises all of the Warrants and converts all of the Debentures purchased in the Financing, Australis will be entitled to nominate a second director for election to the Board.

On 2 November 2018, the Company executed the Investment Agreement and completed the sale of securities pursuant to the Investment Agreement.

#### ***Statement of Cash flows***

During Q1 2019, our net cash decreased by \$224,356 (Q1 2018: increase of \$4,314,572), which included net cash used in operating activities of \$223,799 (Q1 2018 - \$288,969), net cash used in investing activities of \$73,872 (Q1 2018 - \$92,674), net cash provided by financing activities of \$Nil (Q1 2018 - \$4,769,943) and effect of exchange rate changes on cash and cash equivalents of \$73,315 (Q1 2018: (\$73,728)).

#### ***Cash Flow used in Operating Activities***

Cash flow used in operating activities totaled \$223,799 and \$288,969 during Q1 2019 and Q1 2018, respectively. Significant changes in cash used in operating activities are outlined as follows:

- The Company incurred a net loss from operations of \$211,794 during Q1 2019 compared to \$450,508 in Q1 2018. The net loss in Q1 2019 included non-cash depreciation of \$69,557 (Q1 2018 - \$Nil), income tax expenses of \$125,555 (Q1 2018: \$Nil) and foreign exchange of \$738 (Q1 2018 - \$Nil).

The following non-cash items further adjusted the loss for Q1 2019 as follows:

- Increase in amounts receivable and prepaid of \$115,717 (Q1 2018 - \$25,986), increase in inventory of \$159,095 (Q1 2018 - \$Nil), increase in trade payables and accrued liabilities of \$102,343 (Q1 2018 - \$192,330) and a decrease in due to related parties of \$41,006 (Q1 2018 - \$4,805).

#### ***Cash Flow used in Investing Activities***

During Q1 2019, investing activities used cash of \$73,872 compared to \$92,674 during Q1 2018. The change in cash used in investing activities in Q1 2019 compared to Q1 2018 relates primarily to acquisition of NMG Ohio LLC of \$30,000 (Q1 2018 - \$Nil) and additional property and equipment of \$43,872 (Q1 2018 - \$Nil). In Q1 2018, the Company paid \$92,674 to NMG as part of the acquisition that closed in November 2017.

#### ***Cash Flow provided by Financing Activities***

During Q1 2019 the Company did not have any financing activity. In Q1 2018, as part of the Concurrent Financing requirement of the Share Exchange Agreement with NMG, the Company raised \$4,769,943, net of share issue costs, by issuing 9,102,165 Subscription Receipts at a price of CAD\$0.66 per Subscription Receipt. On November 14, 2017, each Subscription Receipt converted into one common share of the Company and one share purchase warrant of the Company exercisable at a price of CAD\$0.90 for a period of 24 months from the date of issuance.

#### ***Off-balance Sheet Arrangements***

The Company has no off-balance sheet arrangements that would require disclosure.

## Subsequent events

On 29 November 2018, the Company and Australis Capital Inc. announced an investment by the Company into Green Light District Holdings, Inc. (“GLDH”) by way of a \$5,200,000 senior secured convertible note at a rate equal to 20% per annum. The note is convertible into 89.75% of the shares of GLDH at the option of the Company. In addition, the Company has an agreement to issue additional consideration to David Barakett totalling \$6,297,580 payable in common shares of the Company at a price of CAD\$0.7439 upon meeting certain milestones. The price was calculated using a 5-day volume weighted average price as of 28 November 2018.

Australis Capital Inc. provided the Company a two-year USD \$4,000,000 loan (“AUSA Debt Financing”) by way of a senior secured note bearing an interest rate of 15% per annum. The terms require semi-annual interest payments unless the Company elects to accrue the interest by adding it to the principal amount of the debt facility. The Company will maintain prepayment rights at any time, in any amount, unless it is within the first year in which case the Company will be required to pay a 5% prepayment penalty on the amount repaid. Additionally, Australis Capital Inc. exercised USD \$1.2m in warrants they held in the Company at an exercise price of CAD \$0.50, which equated to 3,206,160 common shares.

The Company paid a finance fee to Australis Capital Inc. in the amount of 1,105,083 common shares of the Company at a deemed price of CAD \$0.72 per share. The Company also paid a financial advisory fee of CAD \$150,000.

On 11 December 2018, the Company granted an aggregate of 2,050,000 stock options to newly appointed management personnel, in addition to current directors, officers, employees and consultants of the Company, at an exercise price of CAD\$0.57 per share for a five year term expiring 10 December 2023.

## Critical Accounting Policies

Our financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements. In general, management’s estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.

We believe the following critical accounting policies require us to make significant judgments and estimates in the preparation of our consolidated financial statements.

- Income taxes

The determination of deferred income tax assets or liabilities requires subjective assumptions regarding future income tax rates and the likelihood of utilizing tax carry-forwards. Changes in these assumptions could materially affect the recorded amounts, and therefore do not necessarily provide certainty as to their recorded values.

- Foreign currency

The Company determines the functional currency through an analysis of several indicators such as expenses and cash flows, financing activities, retention of operating cash flows, and frequency of transactions with the reporting entity.

- Fair value of financial instruments

Management uses valuation techniques, in measuring the fair value of financial instruments, where active market quotes are not available.

In applying the valuation techniques, management makes maximum use of market inputs wherever possible, and uses estimates and assumptions that are, as far as possible, consistent with observable data that market participants would use in pricing the instrument. Where applicable data is not observable, management uses its best estimate about the assumptions that market participants would make. Such estimates include liquidity risk, credit risk and volatility may vary from the actual results that would be achieved in an arm's length transaction at the reporting date. The assessment of the timing and extent of impairment of intangible assets involves both significant judgements by management about the current and future prospects for the intangible assets as well as estimates about the factors used to quantify the extent of any impairment that is recognized.

- Intellectual property

The recoverability of the carrying value of the intellectual property is dependent on numerous factors. The carrying value of these assets is reviewed by management when events or circumstances indicate that its carrying value may not be recovered. If impairment is determined to exist, an impairment loss is recognized to the extent that the carrying amount exceeds the recoverable amount.

- Stock-based compensation

The option pricing models require the input of highly subjective assumptions, particularly the expected stock price volatility. Changes in the subjective input assumptions can materially affect the fair value estimate, and therefore the existing models do not necessarily provide a reliable single measure of the fair value of the Company's stock options.

### **Recent Accounting Pronouncements**

In February 2016, the FASB issued ASU No. 2016-02 (Topic 842) "Leases." Topic 842 supersedes the lease recognition requirements in Accounting Standards Codification ("ASC") Topic 840 "Leases." Under Topic 842, lessees are required to recognize assets and liabilities on the balance sheet for most leases and provide enhanced disclosures. Leases will continue to be classified as either finance or operating. Topic 842 is effective for annual reporting periods and interim periods within those years beginning after 15 December 2018. Early adoption by public entities is permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements, and there are certain optional practical expedients that an entity may elect to apply. Full retrospective application is prohibited. The Company does not anticipate this amendment to have a significant impact on the financial statements.

In June 2016, the FASB issued ASU No. 2016-13 "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. ASU 2016-13 is effective for annual reporting periods, and interim periods within those years beginning after 15 December 2019. The Company does not anticipate this amendment to have a significant impact on the financial statements.



## Management of financial risks

The financial risk arising from the Company's operations are credit risk, liquidity risk, interest rate risk and currency risk. These risks arise from the normal course of operations and all transactions undertaken are to support the Company's ability to continue as a going concern. The risks associated with these financial instruments and the policies on how to mitigate these risks are set out below. Management manages and monitors these exposures to ensure appropriate measures are implemented on a timely and effective manner.

- Credit risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company is not exposed to credit risk as it does not hold cash in excess of federally insured limits, with major financial institutions.

- Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company had a working capital deficit of \$1,133,314 as at October 31, 2018. In addition, the Company has incurred losses from operations to date and is currently attempting to implement its business plan; therefore, the Company is exposed to liquidity risk.

- Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to interest rate risk as it does not hold financial instruments that will fluctuate in value due to changes in interest rates.

- Currency risk

Currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. The Company is exposed to currency risk by incurring expenditures and holding assets denominated in currencies other than its functional currency. Assuming all other variables remain constant, a 1% change in the Canadian dollar against the US dollar would not result in a significant change to the Company's operations.

- Other risks

The Company is not exposed to other risks unless otherwise noted.

## ITEM 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company does not issue or invest in financial instruments or their derivatives for trading or speculative purposes. The limited operations of the Company were conducted primarily in Canada and the U.S.A., and, are not subject to material foreign currency exchange risk. Although the Company has outstanding debt and related interest expense, market risk of interest rate exposure in the United States is currently not material.

## ITEM 4 – CONTROLS AND PROCEDURES

### (a) Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, Leonard Clough, and our Chief Financial Officer, Darren Tindale, to allow for timely decisions regarding required disclosure. Our Chief Executive Officer and Chief Financial Officer are responsible for establishing and maintaining disclosure controls and procedures for our Company.

Our management has evaluated the effectiveness of our disclosure controls and procedures as of October 31, 2018 (under the supervision and with the participation of the Chief Executive Officer and the Chief Financial Officer), pursuant to Rule 13a-15(b) promulgated under the Securities Exchange Act of 1934, as amended.

As part of such evaluation, management considered the matters discussed below relating to internal control over financial reporting. Based on this evaluation, our Company's Chief Executive Officer and Chief Financial Officer has concluded that our Company's disclosure controls and procedures were effective as of October 31, 2018.

**(b) Internal control over financial reporting**

The term "internal control over financial reporting" is defined as a process designed by, or under the supervision of, the registrant's principal executive and principal financial officers, or persons performing similar functions, and effected by the registrant's board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

- pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the registrant;
- provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the registrant are being made only in accordance with authorizations of management and directors of the registrant; and
- provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the registrant's assets that could have a material effect on the financial statements.

A material weakness is defined in Public Company Accounting Oversight Board Auditing Standard No. 5 as a significant deficiency, or a combination of significant deficiencies, in internal control over financial reporting that results in there being more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected.

There have not been any changes in our internal control over financial reporting that occurred during our fiscal quarter ended October 31, 2018 that have materially affected, or are likely to materially affect, our internal control over financial reporting.

## **PART II – OTHER INFORMATION**

### **ITEM 1 – LEGAL PROCEEDINGS**

The Company is not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, affiliates or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

### **ITEM 1A. RISK FACTORS**

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

### **ITEM 2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

On August 15, 2017 and August 16, 2017, we closed the first two of four tranches of a non-brokered private placement and issued 8,276,294 Subscription Receipts to 116 individuals and 21 entities at a price of CAD\$0.66 per Subscription Receipt for aggregate gross proceeds of CAD\$5,462,369. Each Subscription Receipt automatically converted, at no additional cost to the subscriber, upon the completion of the acquisition of NMG for one common share and one share purchase warrant of the Company. Each warrant entitles the holder to purchase one additional common share of the Company at a price of CAD\$0.90 per warrant for a period of 24 months from the date of issuance.

We relied on exemptions from registration under Regulation S promulgated under the Securities Act for issuances to non-U.S. persons as the securities were issued to the individuals/entities through offshore transactions which were negotiated and consummated outside of the United States and we relied on exemptions from registration under the Securities Act provided by Rule 506 of Regulation D and/or Section 4(a)(2) for issuances to U.S. persons.

On October 31, 2017, we closed a third tranche of a non-brokered private placement and issued 757,666 Subscription Receipts at a price of CAD\$0.66 per Subscription Receipt to one individual for aggregate gross proceeds of CAD\$500,060. Each Subscription Receipt automatically converted, at no additional cost to the subscriber, upon the completion of the acquisition of NMG for one common share and one share purchase warrant of the Company. Each warrant entitles the holder to purchase one additional common share of the Company at a price of CAD\$0.90 per warrant for a period of 24 months from the date of issuance. We relied on exemptions from registration under Regulation S promulgated under the Securities Act for the issuance as the securities were issued to the individual through an offshore transaction which was negotiated and consummated outside of the United States.

On November 10, 2017 we closed a fourth and final tranche of a non-brokered private placement and issued 68,181 Subscription Receipts at a price of CAD\$0.66 per Subscription Receipt to one individual for aggregate gross proceeds of CAD\$45,000. Each Subscription Receipt automatically converted, at no additional cost to the subscriber, upon the completion of the acquisition of NMG for one common share and one share purchase warrant of the Company. Each warrant entitles the holder to purchase one additional common share of the Company at a price of CAD\$0.90 per warrant for a period of 24 months from the date of issuance. We relied on exemptions from registration under Regulation S promulgated under the Securities Act for the issuance as the securities were issued to the individual through an offshore transaction which was negotiated and consummated outside of the United States.

On November 24, 2017, we granted an aggregate of 3,850,000 stock options in accordance with our stock option plan to 19 individuals at an exercise price of CAD\$0.66 per share for a five year term expiring November 24, 2022. We relied on exemptions from registration under Regulation S promulgated under the Securities Act for the option grants to non-U.S. persons and we relied on the exemption from registration under the Securities Act provided by Rule 701 for the option grants to U.S. persons.

On December 1, 2017, we closed a non-brokered private placement of 637,393 units at a price of CAD\$0.66 per unit to five individuals and one entity for aggregate gross proceeds of CAD\$420,680. Each unit consists of one common share and one share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the Company at a price of CAD\$0.90 per warrant for a period of 24 months from the closing. We relied on exemptions from registration under Regulation S promulgated under the Securities Act for issuances to non-U.S. persons as the securities were issued to the individuals/entities through offshore transactions which were negotiated and consummated outside of the United States.

On May 16, 2018, the Company issued 70,500 previously escrowed shares with a fair value of \$31,935 to Toro Pacific Management Inc. in connection with the acquisition of NMG.

On June 6, 2018, we granted 175,000 stock options in accordance with our stock option plan to one individual at an exercise price of CAD\$0.41 per common share for a period of five years expiring on June 6, 2023. We relied on exemptions from registration under Regulation S promulgated under the Securities Act for the option grant to the non-U.S. person.

**ITEM 3 – DEFAULTS UPON SENIOR SECURITIES**

None

**ITEM 4 - MINE SAFETY DISCLOSURES**

None

**ITEM 5 – OTHER INFORMATION**

None

**ITEM 6 – EXHIBITS**

The following exhibits are included with this Quarterly Report:

<u>Exhibit</u>	<u>Description of Exhibit</u>
<a href="#">31.1</a>	<a href="#">Certification of Chief Executive Officer pursuant to the Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).</a>
<a href="#">31.2</a>	<a href="#">Certification of Chief Financial Officer pursuant to the Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).</a>
<a href="#">32.1</a>	<a href="#">Certifications pursuant to the Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definitions Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**BODY AND MIND INC.**

December 21, 2018  
\_\_\_\_\_  
Date

BY: /s/ Leonard Clough  
\_\_\_\_\_  
Leonard Clough, President and Chief Executive Officer  
(Principal Executive Officer)

December 21, 2018  
\_\_\_\_\_  
Date

BY: /s/ Darren Tindale  
\_\_\_\_\_  
Darren Tindale, Chief Financial Officer  
(Principal Financial Officer and Principal Accounting Officer)